Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity

This is another chance for us to make good on our promise to customers of access to affordable, available treatments that meet our high clinical standards, and I cant wait to see the lives we impact
The shift toward parasympathetic tone reduces resting heart rate variability, decreases cardiac workload, and promotes arterial relaxation
This provokes some challenging symptoms, but suggests the treatment is addressing the root cause of the imbalance
The correct term is triple agonist